Among their analogues, the 68Ga-labeled PSMA-11 was the first PET-radiopharmaceutical for targeting PSMA-upregulated lesions in men with PCa and the only metal-based radiopharmaceutical including a small-molecule PSMA-inhibitor pharmacophore approved by the FDA-USA for patients with PCa and suspected biochemical recurrence. This evidence concerns the gene FOLH1 and posterior cortical atrophy.